Zacks Investment Research on MSN
MMED's latest study supports the strength of 780G SmartGuard algorithm
MiniMed Group, Inc. MMED recently announced results from a new randomized crossover study showing that glycemic outcomes remained nearly identical when patients used its MiniMed 780G automated insulin ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results